WAVE Life Sciences Ltd. (WVE) Soars 8.3%

WAVE Life Sciences Ltd. (WVE) Soars 8.3%

WAVE Life Sciences Ltd. (WVE) had a good day on the market for Tuesday December 10 as shares jumped 8.3% to close at $35.11. About 452,757 shares traded hands on 4,549 trades for the day, compared with an average daily volume of n/a shares out of a total float of 34.29 million. After opening the trading day at $32.31, shares of WAVE Life Sciences Ltd. stayed within a range of $35.48 to $32.26.

With today’s gains, WAVE Life Sciences Ltd. now has a market cap of $1.2 billion. Shares of WAVE Life Sciences Ltd. have been trading within a range of $50.98 and $17.60 over the last year, and it had a 50-day SMA of $n/a and a 200-day SMA of $n/a.

WAVE Life Sciences Ltd is a preclinical biopharmaceutical company based in Singapore. It owns a diverse pipeline of nucleic acid therapeutics meant to address rare genetic diseases related to the central nervous system, muscles, eyes, liver, and skin. Its nucleic acid therapeutics target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.

WAVE Life Sciences Ltd. is based out of Singapore, and has some 250 employees. Its CEO is Paul B. Bolno.

WAVE Life Sciences Ltd. is also a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It’s maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell’s indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It’s a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

error: Content is protected !!